Trial Information
Observational Study Assessing Molecular Features Predicting Response/Resistance to Trastuzumab in Metastatic Breast Cancer Patients
Inclusion Criteria:
- Hystological diagnosis of breast cancer
- Availability of tumor tissue
- Availability to assess the response to Trastuzumab according to RECIST criteria
- Availability of clinical data
Exclusion Criteria:
- Unavailability of tumor tissue
- Impossibility to assess the response to Trastuzumab according to RECIST criteria
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Retrospective
Outcome Measure:
Association of a specific biomarker with response to Herceptin-based therapy
Outcome Time Frame:
Response after two months of treatment
Safety Issue:
No
Principal Investigator
Armando Santoro, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Istituto Clinico Humanitas
Authority:
Italy: Ministry of Health
Study ID:
ONC/OSS-01/2007
NCT ID:
NCT00740532
Start Date:
October 2007
Completion Date:
August 2010
Related Keywords:
- Breast Cancer
- EGFR, HER-2, HER-3, MET, KRAS
- Breast Neoplasms